Cystic Fibrosis Drug Sales Should Soar; VX-661/Ivacaftor To Lead Way

Sales of key cystic fibrosis drugs will jump in western economies over the next decade, driven by strong uptake of high-cost CFTR modulator therapies and longer use as life expectancies improve, according to a new report by Datamonitor Healthcare.

Cystic fibrosis word cloud

Sales of key cystic fibrosis drugs are projected to rise across the US and Europe from some $2.6bn in 2016 to $7.2bn in 2025 due to strong demand for high-cost CFTR modulator therapies as patient populations expand and life expectancies improve. Vertex Pharmaceuticals Inc.’s investigational VX-661/ivacaftor combo is likely to lead the pack, according to a new report by Informa’s Datamonitor Healthcare.

Vertex’s investigational CFTR corrector/potentiator combination therapy VX-661/ivacaftor, currently in Phase III trials, looks set to be successful and ride a...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Respiratory

More from Therapeutic Category